Stock futures were cautious in the premarket hours of Wednesday, taking a breather after the previous session’s record highs as investors assessed market conditions and positioned ahead of a pivotal U.S. jobs report later in the week.
Here are some of Wednesday’s biggest stock movers:
Biggest stock gainers
- Ventyx Biosciences (VTYX) +67% – Shares jumped following a report that Eli Lilly (LLY) is in advanced talks to acquire the company. The report, citing people familiar with the matter, indicated that a deal could be announced imminently, sparking a sharp rally in VTYX shares on takeover speculation.
- Mobileye Global (MBLY) +11% – Shares surged after announcing it will acquire humanoid robotics startup Mentee Robotics for about $900M, expanding beyond autonomous driving into humanoid robotics. The deal combines Mobileye’s AI and large-scale production capabilities with Mentee’s humanoid platform, positioning the company to compete in the fast-evolving physical AI space. The acquisition includes roughly $612M in cash and up to 26.2M Mobileye Class A shares, with Mentee operating as an independent unit. CEO Amnon Shashua, who also co-founded Mentee, called the move the start of “Mobileye 3.0,” with initial customer proof-of-concept deployments expected in 2026 and commercialization targeted for 2028. The transaction, approved by Mobileye’s board and Intel, is expected to close in Q1.
- HIVE Digital Technologies (HIVE) +5% – Shares rose after the bitcoin miner reported December 2025 production of 306 BTC, nearly tripling from 103 BTC a year earlier, as higher hashrate and improved fleet efficiency lifted output. Production rose 6% month over month and 23% quarter over quarter, with an average hashrate of 23.3 EH/s and a peak of 24 EH/s. For FY2025, HIVE produced 2,311 bitcoin, up 31% from 1,770 BTC in 2024, and said it plans to add 100 MW of hydro-powered data center capacity at its Yguazú campus in Paraguay by Q3 2026, expanding its renewable footprint to about 540 MW across Paraguay, Canada, and Sweden.
Biggest stock losers
- Bright Minds Biosciences (DRUG) -2% – Shares slipped after announcing a $100M public offering of common shares and pre-funded warrants, with proceeds earmarked to fund upcoming clinical trials across multiple programs, including treatments for absence seizures, developmental and epileptic encephalopathies (DEE), and Prader-Willi Syndrome. The company also plans to initiate Phase 1 clinical trials for BMB-105, advance earlier-stage R&D programs, and support general corporate and working capital needs.